title: Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials.
abstract: Activation of the renin-angiotensin system plays a major role in cardiovascular morbidity and mortality. Recently, angiotensin II receptor blockers (ARBs) have been the subject of a number of large clinical cardiovascular outcome trials, indicating beneficial effects of ARBs with more than 384,000 patient-years of data in different cardiovascular diseases along the cardiovascular continuum, from patients with risk factors, through high cardiovascular risk, to patients with heart failure. This article reviews the implications of these trials for the optimal management of cardiovascular risk.
authors.affiliation: Department of Cardiology, University Hospital of Saarland, Homburg Saar, Germany. magnus@baumhaekel.de
authors.forename: Magnus
authors.initials: M
authors.lastname: Baumhäkel
authors.forename: Michael
authors.initials: M
authors.lastname: Böhm
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism; D002986:Clinical Trials as Topic; D018450:Disease Progression; D019317:Evidence-Based Medicine; D006801:Humans; D012084:Renin-Angiotensin System / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D002317:Cardiovascular Agents